Almac opens CLIA registered laboratory
14 April 2011
Almac has announced the opening of its CLIA registered
laboratory in Northern Ireland. The company says this supports the its ongoing
biomarker discovery and development strategy by enabling the use of
novel tests to stratify and enrich prospective clinical trails.
It sees this of key importance as it begins to transition the novel
biomarkers that they have developed into clinical use, with the
resulting potential to inform the drug development process and
target therapies to responsive patients.
In addition to standard molecular tests, Almac has a pipeline of
both internal clinical tests and companion diagnostic tests with
Pharma partners in development that will be delivered from the Almac
CLIA Laboratory.
Professor Paul Harkin, President and Managing Director of Almac’s
diagnostics business said: “We are very happy to announce the launch
of our CLIA lab, which has been opened to meet both our needs and
the needs for our Pharma partners. We have come to a point where the
biomarkers we have discovered and assays that we have developed are
being used to stratify patients, enrich clinical trials and impact
patient treatment decisions. As such, CLIA is a key necessity for
the processing of these samples.”